Company intelligence / Profile preview
Transposon Therapeutics, Inc.
San Diego, California, United Statestransposonrx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
TPN-101 received FDA Fast Track designation for PSP in May 2024. Phase 2a study in ALS/FTD patients with C9ORF72 mutation showed TPN-101 slowed vital capacity decline in ALS patients, with biomarker responses suggesting therapeutic benefit on neuroinflammation and neurodegeneration. All doses were well-tolerated, and clinical benefit in ALS emerged with prolonged treatment. A Phase 3 clinical trial is in planning.[5][10]
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Transposon Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transposon Therapeutics, Inc..